Cabaletta Bio vs Barinthus Biotherapeutics
Cabaletta Bio
Engineered T cell therapies designed for the treatment of patients with autoimmune diseases
191 employees · est. 2017 · Philadelphia, United States
Barinthus Biotherapeutics
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates
34 employees · est. 2016 · Oxford, United Kingdom
Barinthus Biotherapeutics is the older company (2017 vs 2016); Cabaletta Bio is the larger of the two.
Side-by-Side Comparison
| Metric | Cabaletta Bio | Barinthus Biotherapeutics |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2016 older |
| Headquarters | ||
| Headquarters | Philadelphia, United States | Oxford, United Kingdom |
| Employees | ||
| Employees | 191 larger | 34 |
| Industry | ||
| Industry | Biotechnology, Pharmaceutical | Biotechnology, Health and Wellness, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | IPO | Acquired |
| Total Funding | ||
| Total Funding | $322.00M | $146.66M |
| Funding Rounds | ||
| Funding Rounds | 8 | 7 |
| Services | ||
| Services | Development of T cell therapies for autoimmune diseases, Conducting Phase 1/2 clinical trials, CD19 chimeric antigen receptor T cell therapy development, Research and development of CABA® platform | Development of antigen-specific immunotherapies, Phase 1b/2 clinical trials, Pipeline management for autoimmune diseases and chronic viral infections, Biopharmaceutical research and development |
| Target Customers | ||
| Target Customers | Patients with autoimmune diseases, Healthcare providers specializing in rheumatology, dermatology, and neurology, Biotechnology researchers and collaborators, Investors in biopharmaceuticals | Patients with autoimmune and inflammatory conditions, Patients with chronic viral infections, Healthcare providers, Oncologists |
| Taxonomy | ||
| Taxonomy | Engineered T Cell TherapiesAutoimmune DiseasesClinical-stageCARTA StrategyCAART StrategyB Cell-mediated Autoimmune Diseases +8 | T-cell ImmunotherapeuticsChronic Infectious DiseasesAutoimmunityCancer TreatmentChAdOx TechnologyMVA Boost Vector +9 |
| Website | ||
| Website | cabalettabio.com | barinthusbio.com |
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is at the forefront of innovation within the biotechnology sector, focusing on engineered T cell therapies aimed at treating autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, PA, this clinical-stage company is pioneering potentially curative medical...
About Barinthus Biotherapeutics
Barinthus Biotherapeutics, founded in 2016, is a United Kingdom-based clinical-stage biopharmaceutical company that is innovating in the realms of Biotechnology, Health and Wellness, and Pharmaceutical industries. The company specializes in developing novel T-cell immunotherapeutic candidates aimed...
Also comparing in this category
Comparing more than these two?
Get Cabaletta Bio, Barinthus Biotherapeutics and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does Cabaletta Bio compare?
A PDF of Cabaletta Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Frequently Asked Questions
Compare Cabaletta Bio with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Cabaletta Bio on 9 Jun 2026, and Barinthus Biotherapeutics on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
